The progressive pathway of microalbuminuria: From early marker of renal damage to strong cardiovascular risk predictor

Journal of Hypertension

Volumn 28, Issue 12, 2010, Pages 2357-2369

  Cerasola, Giovanni ^a   Cottone, Santina ^a   Mulè, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Arterial hypertension; Cardiovascular risk; Microalbuminuria; Target organ damage; Urinary albumin excretion

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; BIOLOGICAL MARKER;

AGING; ARTERIAL STIFFNESS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CIGARETTE SMOKING; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; URINARY EXCRETION; ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY;

ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES;

EID: 79956311037     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833ec377     Document Type: Review

References (125)

1. Svendsen PA, Oxenball B, Christiansen JS. Microalbuminuria in diabetic patients: A longitudinal study. Acta Endocrinol Suppl (Copenh) 1981; 242:53-54.
2. Viberti GC, Hill RD, Jarret RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulindependent diabetes mellitus. Lancet 1982; I:1430-1432. (Pubitemid 12123979)
3. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 31:89-93. (Pubitemid 14084080)
4. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310:356-360. (Pubitemid 14179541)
5. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426. (Pubitemid 32681484)
6. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
7. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32-35. (Pubitemid 38880131)
8. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005; 112:969-975. (Pubitemid 41170264)
9. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int 2006; 70:1214-1222. (Pubitemid 44435172)
10. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526. (Pubitemid 32823860)
11. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. Microalbuminuria and stroke in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 2004; 255:247-256. (Pubitemid 38241369)
12. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, et al. Microalbuminuria in nondiabetic adults: Relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158:1933-1939. (Pubitemid 28440868)
13. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30:1135-1143. (Pubitemid 27476170)
14. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16:79-89. (Pubitemid 34182916)
15. Bramlage P, Pittrow D, Lehnert H, Höfler M, Kirch W, Ritz E, Wittchen HU. Frequency of albuminuria in primary care: A cross-sectional study. Eur J Cardiovasc Prev Rehabil 2007; 14:107-113.
16. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298:2038-2047. (Pubitemid 350074801)
17. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223-228. (Pubitemid 26121865)
18. Cerasola G, Mulè G, Nardi E, Cusimano P, Palermo A, Arsena R, et al. Clinical correlates of renal dysfunction in hypertensive patients without cardiovascular complications: The REDHY study. J Hum Hypertens 2010; 24:44-50.
19. Cerasola G, Mulè G, Cottone S, Nardi E, Cusimano P. Hypertension, microalbuminuria and renal dysfunction: The Renal Dysfunction in Hypertension (REDHY) study. J Nephrol 2008; 21:368-373.
20. Leoncini G, Viazzi F, Agabiti Rosei E, Ambrosioni E, Costa FV, Leonetti G, et al. Chronic kidney disease in hypertension under specialist care: The I-DEMAND study. J Hypertens 2010; 28:156-162.
21. Böhm M, Thoenes M, Danchin N, Bramlage P, La Puerta P, Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: The i-SEARCH global study. J Hypertens 2007; 25:2317-2324. (Pubitemid 47537927)
22. Mountokalakis TD. The renal consequences of hypertension. Kidney Int 1997; 51:1639-1653.
23. Dworkin LD, Ichikawa I, Brenner BM. Hormonal modulation of glomerular function. Am J Physiol 1983; 244:F95-F104. (Pubitemid 13138667)
24. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potential adverse response to renal ablation. Am J Physiol 1981; 241:F85-F93. (Pubitemid 11033923)
25. Cottone S, Cerasola G. Microalbuminuria fractional clearance and early renal permselectivity changes in essential hypertension. Am J Nephrol 1992; 12:326-329. (Pubitemid 23039906)
26. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed- Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32:219-226. (Pubitemid 19136363)
27. Pedrinelli R, Giampietro O, Cammassi F, Melillo E, Dell'Olmo G, Catapano G. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14-18. (Pubitemid 24199418)
28. Cottone S, Vadalà A, Mangano MT, Vella MC, Riccobene R, Neri AL, et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13:172-176. (Pubitemid 30125640)
29. Cottone S, Mulè G, Nardi E, Lorito MC, Guarneri M, Arsena R, Cerasola G. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 2007; 21:167-172.
30. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, et al. Oxidative stress and glomerular filtration barrier injury: Role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006; 291:F1308-F1314. (Pubitemid 44887244)
31. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, Penno G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24:2414-2419. (Pubitemid 39658051)
32. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22:593-598. (Pubitemid 34408739)
33. Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008; 101:401-406. (Pubitemid 351175628)
34. Comper WD, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis 2005; 12:170-176. (Pubitemid 40488999)
35. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, Classification, and Stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002; 39(Suppl 1):S46-S75
36. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187.
37. Redon J, Williams B. Microalbuminuria in essential hypertension. Redefining the threshold. J Hypertens 2002; 20:353-355. (Pubitemid 34913726)
38. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Low muscular mass and overestimation of microalbuminuria by urinary albumin/creatinine ratio. Hypertension 2006; 47:56-61. (Pubitemid 43177816)
39. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al. Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54:205-226.
40. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572-581.
41. Cerasola G, Cottone S, D'Ignoto G, Grasso L, Mangano MT, Andronico G. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989; 7 (Suppl 6): S332-S333. (Pubitemid 20090989)
42. Cerasola G, Cottone S, Mulè G, Nardi E, Mangano MT, AndronicoG, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14:915-920. (Pubitemid 26237214)
43. Hsu CC, Brancati FL, Astor BC, Kao WH, Steffes MW, Folsom AR, Coresh J. Blood pressure, atherosclerosis, and albuminuria in 10 113 participants in the Atherosclerosis Risk in Communities Study. J Hypertens 2009; 27:397-409.
44. Palatini P, Graniero GR, Canali C, Santonastaso M, Mos L, Piccolo D, et al. Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension. J Hypertens 1995; 13:1796-1800. (Pubitemid 26015819)
45. Cerasola G, Cottone S, Nardi E, D'Ignoto G, Volpe V, Mulé G, Carollo C. White-coat hypertension and cardiovascular risk. J Cardiovasc Risk 1995; 2:545-549. (Pubitemid 26135331)
46. Bianchi S, Bigazzi R, Baldari G, Sgherri GP, Campese VM. Diurnal variation of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7:23-29. (Pubitemid 24033215)
47. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797-805. (Pubitemid 34988338)
48. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int 1999; 56 (Suppl 7):S10-S13. (Pubitemid 29304803)
49. Cerasola G, Cottone S. Microalbuminuria as a marker of vascular damage in hypertension: Influence of blood pressure and metabolic patterns. Nutr Metab Cardiovasc Dis 1997; 7:92-95. (Pubitemid 127547099)
50. Mule G, Cottone S, Mongiovì R, Cusimano P, Mezzatesta G, Seddio G, et al. Influence of metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 2006; 16:54-59.
51. Palaniappan L. Carnethon M, and Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16:952-958. (Pubitemid 37315495)
52. Andronico G, Ferrara L, Mangano M,Mulè G, CerasolaG. Insulin, sodiumlithium countertransport, and microalbuminuria in hypertensive patients. Hypertension 1998; 31:110-113. (Pubitemid 28124701)
53. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabetes 1998; 47:793-800. (Pubitemid 28201810)
54. Srinivasan SR, Myers L, Berenson GS. Risk variables of insulin resistance syndrome in African American and Caucasian young adults with microalbuminuria: The Bogalusa Heart Study. Am J Hypertens 2000; 13:1274-1279.
55. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: The Hoorn Study. Diabetologia 1998; 41:694-700. (Pubitemid 28261405)
56. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med 1998; 15:539-553. (Pubitemid 28319935)
57. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257:503-513. (Pubitemid 40776510)
58. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998. (Pubitemid 39336683)
59. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: Impact on cardiovascular disease and mortality. J Intern Med 2007; 262:470-478. (Pubitemid 47404367)
60. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int 2006; 69:2057-2063. (Pubitemid 43924271)
61. Andronico G, Romé M, Lo Cicero A, Parsi R, Seddio G, Ferraro-Mortellaro R, Cerasola G. Renal plasma flow, filtration fraction and microalbuminuria in hypertensive patients: Effects of chronic smoking. Nephrology (Carlton) 2005; 10:483-486. (Pubitemid 41727273)
62. Mulè G, Cottone S, Cusimano P, Riccobene R, Palermo A, Geraci C, et al. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension. Am J Hypertens 2009; 22:1041-1047.
63. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20:1069-1077.
64. van der Velde M, Halbesma N, de Charro FT, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20:852-862.
65. Bigazzi R, Bianchi S, Baldari S, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333. (Pubitemid 28408416)
66. Cerasola G, Mulè G, Nardi E, Cottone S, Andronico G, Mongiovì R, Mezzatesta G. Usefulness of microalbuminuria in cardiovascular risk stratification of essential hypertensive patients. Nephron Clin Pract 2004; 96:c23-c30.
67. Pontremoli R, Ravera M, Bezante GP, Viazzi F, Nicolella C, Berruti V, et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17:993-1000. (Pubitemid 29322188)
68. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
69. Dell'Omo G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254:76-84. (Pubitemid 36819132)
70. Ratto E, Leoncini G, Viazzi F, Bezante GP, Falqui V, Parodi A, et al. Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. J Hypertens 2008; 26:345-350.
71. Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, de Jong PE, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large nondiabetic population. The PREVEND (Prevention of Renal and Vascular ENdstage Disease) study. Eur Heart J 2000; 21:1922-1927.
72. Sciarretta S, Pontremoli R, Rosei EA, Ambrosioni E, Costa V, Leonetti G, et al. Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: Data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2009; 27:410-417.
73. Tuttle KR, Puhlman ME, Cooney SK, Short R. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis 1999; 34:918-925. (Pubitemid 29521710)
74. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9:827-833.
75. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004; 66:448-454. (Pubitemid 38870124)
76. Rodondi N, Yerly P, Gabriel A, Riesen WF, BurnierM, Paccaud F, Bovet P. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant 2007; 22:1107-1114. (Pubitemid 46523425)
77. Furtner M, Kiechl S, Mair A, Seppi K, Weger S, Oberhollenzer F, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J 2005; 26:279-287. (Pubitemid 40222366)
78. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 2007; 255:27-34. (Pubitemid 46414018)
79. Jørgensen L, Jenssen T, Johnsen SH, Mathiesen EB, Heuch I, Joakimsen O, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in nondiabetic persons: The Tromsø Study. Eur Heart J 2007; 28:363-369.
80. Malik AR, Sultan S, Turner ST, Kullo IJ. Urinary albumin excretion is associated with impaired flow- and nitroglycerin-mediated brachial artery dilatation in hypertensive adults. J Hum Hypertens 2007; 21:231-238.
81. Mulè G, Cottone S, Cusimano P, Palermo A, Geraci C, Nardi E, et al. Unfavourable interaction of microalbuminuria and mildy reduced creatinine clearance on aortic stiffness in essential hypertension. Int J Cardiol 2010. [Epub ahead of print]
82. Mulè G, Cottone S, Vadalà A, Volpe V, Mezzatesta G, Mongiovì R, et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256:22-29. (Pubitemid 38813616)
83. Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: The Hoorn Study. J Am Soc Nephrol 2007; 18:1942-1952. (Pubitemid 46870332)
84. Munakata M, Miura Y, Yoshinaga K, J-TOPP study group. Higher brachialankle pulse wave velocity as an independent risk factor for future microalbuminuria in patients with essential hypertension: The J-TOPP study. J Hypertens 2009; 27:1466-1471.
85. Shantha GP, Kumar AA, Bhaskar E, Sivagnanam K, Srinivasan D, Sundaresan M, et al. Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: A cross-sectional study. Nephrol Dial Transplant 2010; 25:1839-1845.
86. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9:iii-vi, xiii-163.
87. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus: A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418. (Pubitemid 27300386)
88. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. on behalf of the ADVANCE Collaborative Group Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. J Am Soc Nephrol 2009; 20:1813-1821.
89. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol 2008; 19:1785-1791.
90. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003; 139:901-906.
91. Jørgensen L, Jenssen T, Heuch I, Jacobsen BK. The combined effect of albuminuria and inflammation on all-cause and cardiovascular mortality in nondiabetic persons. J Intern Med 2008; 264:493-501.
92. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167:1226-1234. (Pubitemid 351670638)
93. Cirillo M, Lanti MP, Menotti A, Laurenzi M, Mancini M, Zanchetti A, De Santo NG. Definition of kidney dysfunction as a cardiovascular risk factor: Use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med 2008; 168:617-624. (Pubitemid 351471667)
94. Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: Associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167:1386-1392. (Pubitemid 47052437)
95. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639. (Pubitemid 44969122)
96. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, et al. The relationship between proteinuria and coronary risk: A systematic review and meta-analysis. PLoS Med 2008; 5:e207.
97. Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, et al. Proteinuria and stroke: A meta-analysis of cohort studies. Am J Kidney Dis 2009; 53:417-425.
98. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, et al., LIFE Study Investigators. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The LIFE study. Am J Hypertens 2008; 21:273-279. (Pubitemid 351323279)
99. Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, et al., HOPE Investigators. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:1284-1290. (Pubitemid 36314412)
100. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al., CHARM Investigators and Committees. Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet 2009; 374:543-550.
101. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005; 28:2525-2530. (Pubitemid 41384305)
102. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Lowgrade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111:1370-1376. (Pubitemid 40396802)
103. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, et al. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension 1999; 34:491-495. (Pubitemid 29426769)
104. Diercks GFH, Stroes ESG, van Boven AJ, van Roon AM, Hillege HL, de Jong PE, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis 2002; 163:121-126. (Pubitemid 34615733)
105. Redon J. Renal protection by antihypertensive drugs: Insights from microalbuminuria studies. J Hypertens 1998; 16:2091-2100. (Pubitemid 29002393)
106. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134:370-379.
107. Viberti GC, Wheelden NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressureindependent effect. Circulation 2002; 106:672-678.
108. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:253-259.
109. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
110. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
111. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927. (Pubitemid 39128617)
112. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65:2309-2320. (Pubitemid 38670018)
113. Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al., for the Prevention of Renal and Vascular Endstage Disease Intervention Trial investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816. (Pubitemid 39473602)
114. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805-1811. (Pubitemid 39141974)
115. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45:198-202. (Pubitemid 40179960)
116. Parving HH, Lehnert H, Brochner-Mortenson J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
117. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
118. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
119. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardioprotective effects of direct renin inhibition: A systematic literature review. J Hypertens 2009; 27:2321-2331.
120. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
121. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study. J Hypertens 2004; 22:1613-1622. (Pubitemid 39037614)
122. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685. (Pubitemid 28306794)
123. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27:S79-S83.
124. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 2006; 70:1223-1233. (Pubitemid 44435173)
125. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145:117-124. (Pubitemid 46780585)